This presentation by James Q. Del Rosso, DO, focused on recent findings in dermatologic therapies. Starting with dupilumab, a study reported that dupilumab can be an effective treatment for AD when readministered after discontinuation. For patients who do not respond well to initial biologic treatments, small molecule alternatives like tralokinumab, upadacitinib, and abrocitinib have shown promise in achieving better skin clearance and itch relief. The LEVEL UP open-label comparison trial showed that upadacitinib may be even more effective for treating AD. Dr Del Rosso also highlighted new research on the pathogenesis of AD and thus the development of targeted therapies. TheOX40-OX40L-activated pathway has been shown to potentially play a role in AD, and there are several therapies currently in clinical trials that inhibit OX40-OX40L binding. 

He further discussed emerging information on various treatments for psoriasis, hidradenitis suppurativa (HS), and chronic spontaneous urticaria (CSU) treatments, which all aim to target specific factors in the evolving pathogenesis of these conditions. 

Lastly, the discussion touched on real-world challenges of recommending supplements with polypodium leucotomos (PL) or PL extract (PLE). PLE can have beneficial protective skin effects; however, it is noted that using the methods of extraction, production techniques, and extract use change the efficacy of the products.